aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
Company profile
Ticker
AUPH
Exchange
Website
CEO
Peter Greenleaf
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aurinia Pharma U.S., Inc. • Aurinia Pharma Limited ...
AUPH stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
3 May 24
DEFA14A
Additional proxy soliciting materials
3 May 24
DEF 14A
Definitive proxy
3 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
2 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
15 Feb 24
8-K
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
5 Jan 24
Transcripts
AUPH
Earnings call transcript
2024 Q1
2 May 24
AUPH
Earnings call transcript
2023 Q4
15 Feb 24
AUPH
Earnings call transcript
2023 Q3
2 Nov 23
AUPH
Earnings call transcript
2023 Q2
3 Aug 23
AUPH
Earnings call transcript
2023 Q1
4 May 23
AUPH
Earnings call transcript
2022 Q4
28 Feb 23
AUPH
Earnings call transcript
2022 Q3
3 Nov 22
AUPH
Earnings call transcript
2022 Q2
4 Aug 22
AUPH
Earnings call transcript
2022 Q1
10 May 22
AUPH
Earnings call transcript
2021 Q4
28 Feb 22
Latest ownership filings
SC 13D/A
ILJIN SNT Co., Ltd.
20 Mar 24
4
Peter Greenleaf
7 Mar 24
4
Joseph M Miller
7 Mar 24
4
Matthew Maxwell Donley
7 Mar 24
4
Scott Michael Habig
7 Mar 24
4
Stephen P. Robertson
7 Mar 24
4
Volker Knappertz
29 Feb 24
4
Volker Knappertz
22 Feb 24
4
Scott Michael Habig
22 Feb 24
4
Matthew Maxwell Donley
22 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm |
Cash burn (monthly) | 11.77 mm | 3.30 mm | 5.42 mm | 7.51 mm | 4.43 mm | 3.11 mm |
Cash used (since last report) | 86.93 mm | 24.41 mm | 40.04 mm | 55.46 mm | 32.69 mm | 22.97 mm |
Cash remaining | -40.53 mm | 21.99 mm | 6.36 mm | -9.07 mm | 13.71 mm | 23.43 mm |
Runway (months of cash) | -3.4 | 6.7 | 1.2 | -1.2 | 3.1 | 7.5 |
Institutional ownership, Q4 2023
26.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 134 |
Opened positions | 18 |
Closed positions | 81 |
Increased positions | 42 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 272.87 bn |
Total shares | 37.62 mm |
Total puts | 293.00 k |
Total calls | 735.80 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 9.54 mm | $85.73 bn |
ILJIN SNT | 6.06 mm | $0.00 |
NEA Management | 3.97 mm | $35.69 bn |
STT State Street | 2.70 mm | $24.31 bn |
GS Goldman Sachs | 2.05 mm | $18.42 bn |
MS Morgan Stanley | 1.45 mm | $13.08 bn |
C Citigroup | 1.42 mm | $12.74 bn |
NTRS Northern Trust | 1.07 mm | $9.59 bn |
Woodline Partners | 645.19 k | $5.80 bn |
Jane Street | 582.49 k | $5.24 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Greenleaf Peter | Common Stock | Sell | Dispose S | No | No | 5.6 | 126,981 | 711.09 k | 1,522,114 |
6 Mar 24 | Miller Joseph M | Common Stock | Sell | Dispose S | No | No | 5.6 | 34,811 | 194.94 k | 495,928 |
6 Mar 24 | Matthew Maxwell Donley | Common Stock | Sell | Dispose S | No | No | 5.51 | 40,665 | 224.06 k | 584,072 |
6 Mar 24 | Scott Michael Habig | Common Stock | Sell | Dispose S | No | No | 5.6 | 17,777 | 99.55 k | 474,587 |
6 Mar 24 | Stephen P. Robertson | Common Stock | Sell | Dispose S | No | No | 5.6 | 57,745 | 323.37 k | 443,824 |
News
Aurinia Reports Presentation Of Two Studies At The Annual Congress Of Clinical Rheumatology
9 May 24
Aurinia Pharmaceuticals Shareholder Urges Board Of Directors To Take Action To Enhance Shareholder Value; Outlines Concerns Regarding The Company's Current Strategy And Board Composition And Offers Superior Paths To Improving Performance And Market Penetration
7 May 24
Aurinia Pharmaceuticals Q1 2024 GAAP EPS $(0.07) Beats $(0.14) Estimate, Sales $50.300M Beat $47.453M Estimate
2 May 24
FDA Approves Updated LUPKYNIS (voclosporin) Label To Include Long-Term Data From The AURORA Clinical Program
30 Apr 24
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
1 Mar 24
Press releases
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
9 May 24
Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
7 May 24
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
7 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
2 May 24
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
1 May 24